Themis Bioscience is a vaccine development company based in Vienna, Austria. The lead product is a vaccine against the tropical disease Chikungunya which is in late-stage clinical testing. In addition, Themis leveraged their vaccine platform technology to start developing a vaccine against Covid-19.
Themis Bioscience was acquired by MSD in May 2020.
YEAR OF INVESTMENT
YEAR OF EXIT